Drug Profile
Research programme: thrombosis therapeutics - Affimed Therapeutics
Alternative Names: AFM 14; anti gpIIb/IIIa; Thrombosis therapeutics research programme - Affimed TherapeuticsLatest Information Update: 22 Jul 2010
Price :
$50
*
At a glance
- Originator Affimed Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Dec 2006 Preclinical trials in Thrombosis in Australia (unspecified route)
- 25 Jul 2005 This programme is available for licensing (http://www.affimed.com)
- 25 Jun 2005 Preclinical trials in Thrombosis in Germany (unspecified route)